Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|4|2|137-142

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.4, Iss.2, 2015-03, pp. : 137-142

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vascular endothelial growth factor tyrosine kinase inhibitors

By  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 6, 2004-06 ,pp. : 921-924

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

By Swaisland H.  

Clinical Pharmacokinetics, Vol. 40, Iss. 4, 2001-01 ,pp. : 297-306

Adis International

Access to resources Recommend Favorite

Exploring QSARs of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Tyrosine Kinase Inhibitors by MLR, PLS and PC-ANN

By  

Current Pharmaceutical Design, Vol. 19, Iss. 12, 2013-01 ,pp. : 2237-2244

Bentham Science Publishers

Access to resources Recommend Favorite

The effect of food on the pharmacokinetics of tivozanib hydrochloride

By  

Clinical Pharmacology In Drug Development, Vol. 3, Iss. 2, 2014-03 ,pp. : 158-162

John Wiley & Sons Inc

Access to resources Recommend Favorite

A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

By Iyer Renuka   Bharthuar Anubha  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 311-320

Informa Healthcare

Access to resources Recommend Favorite